This company is no longer active
3DMA Stock Overview
A clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Kintara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.95 |
| 52 Week High | US$140.70 |
| 52 Week Low | US$2.45 |
| Beta | 0.81 |
| 1 Month Change | 21.69% |
| 3 Month Change | -17.08% |
| 1 Year Change | -95.01% |
| 3 Year Change | -99.47% |
| 5 Year Change | n/a |
| Change since IPO | -99.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3DMA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 29.8% | -0.3% | 1.7% |
| 1Y | -95.0% | -13.7% | 16.5% |
Return vs Industry: 3DMA underperformed the German Biotechs industry which returned -10.3% over the past year.
Return vs Market: 3DMA underperformed the German Market which returned 14.9% over the past year.
Price Volatility
| 3DMA volatility | |
|---|---|
| 3DMA Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 3DMA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3DMA's weekly volatility has decreased from 33% to 17% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Robert Hoffman | www.kintara.com |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.
Kintara Therapeutics, Inc. Fundamentals Summary
| 3DMA fundamental statistics | |
|---|---|
| Market cap | €375.25m |
| Earnings (TTM) | -€7.85m |
| Revenue (TTM) | n/a |
Is 3DMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3DMA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.50m |
| Earnings | -US$8.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3DMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/18 14:30 |
| End of Day Share Price | 2024/10/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kintara Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Robert Wasserman | Dawson James Securities |
| Jason McCarthy | Maxim Group |